Regulation of immunity during visceral Leishmania infection
- PMID: 26932389
- PMCID: PMC4774109
- DOI: 10.1186/s13071-016-1412-x
Regulation of immunity during visceral Leishmania infection
Abstract
Unicellular eukaryotes of the genus Leishmania are collectively responsible for a heterogeneous group of diseases known as leishmaniasis. The visceral form of leishmaniasis, caused by L. donovani or L. infantum, is a devastating condition, claiming 20,000 to 40,000 lives annually, with particular incidence in some of the poorest regions of the world. Immunity to Leishmania depends on the development of protective type I immune responses capable of activating infected phagocytes to kill intracellular amastigotes. However, despite the induction of protective responses, disease progresses due to a multitude of factors that impede an optimal response. These include the action of suppressive cytokines, exhaustion of specific T cells, loss of lymphoid tissue architecture and a defective humoral response. We will review how these responses are orchestrated during the course of infection, including both early and chronic stages, focusing on the spleen and the liver, which are the main target organs of visceral Leishmania in the host. A comprehensive understanding of the immune events that occur during visceral Leishmania infection is crucial for the implementation of immunotherapeutic approaches that complement the current anti-Leishmania chemotherapy and the development of effective vaccines to prevent disease.
Figures
Comment in
-
Comment on "Regulation of immunity during visceral Leishmania infection" and further discussions about the role of antibodies in infections with Leishmania.Parasit Vectors. 2016 Jul 7;9(1):386. doi: 10.1186/s13071-016-1669-0. Parasit Vectors. 2016. PMID: 27387545 Free PMC article.
Similar articles
-
Immunity to visceral leishmaniasis: implications for immunotherapy.Future Microbiol. 2014;9(7):901-15. doi: 10.2217/fmb.14.43. Future Microbiol. 2014. PMID: 25156379 Review.
-
T-cell populations and cytokine expression are impaired in thymus and spleen of protein malnourished BALB/c mice infected with Leishmania infantum.PLoS One. 2014 Dec 23;9(12):e114584. doi: 10.1371/journal.pone.0114584. eCollection 2014. PLoS One. 2014. PMID: 25535967 Free PMC article.
-
IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology.Eur J Immunol. 2000 Mar;30(3):834-9. doi: 10.1002/1521-4141(200003)30:3<834::AID-IMMU834>3.0.CO;2-9. Eur J Immunol. 2000. PMID: 10741399
-
Parasite burden in hamsters infected with two different strains of leishmania (Leishmania) infantum: "Leishman Donovan units" versus real-time PCR.PLoS One. 2012;7(10):e47907. doi: 10.1371/journal.pone.0047907. Epub 2012 Oct 24. PLoS One. 2012. PMID: 23112869 Free PMC article.
-
Mechanisms of resistance and susceptibility to experimental visceral leishmaniosis: BALB/c mouse versus Syrian hamster model.Vet Res. 2011 Feb 23;42(1):39. doi: 10.1186/1297-9716-42-39. Vet Res. 2011. PMID: 21345200 Free PMC article. Review.
Cited by
-
In vitro and in vivo immunomodulatory properties of octyl-β-D-galactofuranoside during Leishmania donovani infection.Parasit Vectors. 2019 Dec 23;12(1):600. doi: 10.1186/s13071-019-3858-0. Parasit Vectors. 2019. PMID: 31870416 Free PMC article.
-
Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.Front Immunol. 2018 Jan 12;8:1943. doi: 10.3389/fimmu.2017.01943. eCollection 2017. Front Immunol. 2018. PMID: 29375567 Free PMC article. Review.
-
Total serum N-glycans mark visceral leishmaniasis in human infections with Leishmania infantum.iScience. 2023 Jun 5;26(7):107021. doi: 10.1016/j.isci.2023.107021. eCollection 2023 Jul 21. iScience. 2023. PMID: 37485378 Free PMC article.
-
Phenotypical Characterization of Spleen Remodeling in Murine Experimental Visceral Leishmaniasis.Front Immunol. 2020 Apr 15;11:653. doi: 10.3389/fimmu.2020.00653. eCollection 2020. Front Immunol. 2020. PMID: 32351510 Free PMC article.
-
VCAM-1 and ICAM-1 Serum Levels as Markers of Relapse in Visceral Leishmaniasis.Mediterr J Hematol Infect Dis. 2017 Jan 1;9(1):e2017011. doi: 10.4084/MJHID.2017.011. eCollection 2017. Mediterr J Hematol Infect Dis. 2017. PMID: 28101315 Free PMC article. No abstract available.
References
-
- Control of the leishmaniasis: Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases [http://whqlibdoc.who.int/trs/WHO_TRS_949_eng.pdf]
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
